<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333305</url>
  </required_header>
  <id_info>
    <org_study_id>P081107</org_study_id>
    <nct_id>NCT02333305</nct_id>
  </id_info>
  <brief_title>Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10</brief_title>
  <acronym>AOA1</acronym>
  <official_title>Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a study on Ataxia with oculomotor apraxia type 1 (AOA1) in which Coenzyme Q10&#xD;
      (CoQ10) deficit has been observed. Main objectives of the study are :&#xD;
&#xD;
        -  To monitor evolution of albumin in patients affected with AOA1 while supplemented with&#xD;
           CoQ10 ;&#xD;
&#xD;
        -  To measure with clinical scales and biological markers efficacy of supplementation on&#xD;
           disease evolution.&#xD;
&#xD;
      AOA1 is characterised by Hypoalbuminemia. Disease duration is negatively correlated with&#xD;
      albumin level. This study aims to understand mechanisms of the disease and our hypothesis is&#xD;
      that correction or stabilization of albumin level with CoQ10 supplementation could impact&#xD;
      disease evolution. The study is planned from 1 to 2 years supplementation. The CoQ10 is&#xD;
      classified as a food supplement and has already been tested in other neurological conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ataxia with ocular apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia.&#xD;
      Patients' phenotype associates early onset cerebellar ataxia, oculomotor apraxia, neuropathy&#xD;
      and often intellectual disability, hypoalbuminaemia and hypercholesterolemia.&#xD;
&#xD;
      APTX gene mutations responsible for AOA1 disease were identified in a family previously&#xD;
      reported with ataxia and Coenzyme Q10 deficiency. Therefore we measured muscle Coenzyme Q10&#xD;
      in six patients AOA1 and found decreased levels in five. Hypercholesterolaemia and low&#xD;
      albumin levels represent hallmarks of the disease.&#xD;
&#xD;
      We thus propose therapeutic trial with Coenzyme Q10 in AOA1 patients, by using albumin&#xD;
      evolution as primary endpoint.&#xD;
&#xD;
      Moreover several secondary endpoints will be performed:&#xD;
&#xD;
        -  clinical examination (SARA scale)&#xD;
&#xD;
        -  quantitative assessments of the ataxia (with the calculation of the Composite Cerebellar&#xD;
           Functional Severity CCFS)&#xD;
&#xD;
        -  biological criteria (prealbumin, cholesterol, alphafoetoprotein, blood count, hepatic&#xD;
           checkup)&#xD;
&#xD;
        -  oculographic examination.&#xD;
&#xD;
      The study is a multicentric randomised placebo controlled trial with two-year follow-up:&#xD;
&#xD;
        -  during the first year, one group will be supplemented with Coenzyme Q10 while the other&#xD;
           group will receive a placebo;&#xD;
&#xD;
        -  during the second year, all patients will be supplemented with Coenzyme Q10 in order to&#xD;
           assess long term safety and tolerance of the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>coenzyme Q10</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Albuminemia</measure>
    <time_frame>2 years</time_frame>
    <description>Evolution of albuminemia every 6 months during 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARA scale</measure>
    <time_frame>2 years</time_frame>
    <description>Evolution of clinical criteria (SARA and CCFS, which represent quantitative scales to assess cerebellar ataxia evolution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCFS</measure>
    <time_frame>2 years</time_frame>
    <description>Evolution of clinical criteria (SARA and CCFS, which represent quantitative scales to assess cerebellar ataxia evolution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prealbuminemia</measure>
    <time_frame>2 years</time_frame>
    <description>Evolution of biological criteria (prealbuminemia, cholesterol, alfa-foeto-protein) every 6 months during 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholesterol</measure>
    <time_frame>2 years.</time_frame>
    <description>Evolution of biological criteria (prealbuminemia, cholesterol, alfa-foeto-protein) every 6 months during 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alfa-foeto-protein</measure>
    <time_frame>2 years.</time_frame>
    <description>Evolution of biological criteria (prealbuminemia, cholesterol, alfa-foeto-protein) every 6 months during 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oculomotor evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Oculomotor evaluation to assess oculo motor apraxia evolution [Time Frame: Each year during 2 years.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D - PHQ9</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life evolution (self-administered questionnaire EQ5D - PHQ9) every 6 months during 2 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Ataxia-oculomotor Apraxia 1</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CoQ10</intervention_name>
    <description>• 2 dosages according to patient weight: Weight &lt; 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sanomit Placebo</intervention_name>
    <description>• according to patient weight: Weight &lt; 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  1. Diagnosis of ataxia with oculomotor apraxia type I (AOA1) confirmed by genetic&#xD;
             molecular analysis&#xD;
&#xD;
          -  2. Age ≥ 18 years&#xD;
&#xD;
          -  3. Hypoalbuminemia&#xD;
&#xD;
          -  4. Efficient contraception for women of childbearing potential (with pregnancy test&#xD;
             during each visit)&#xD;
&#xD;
          -  5. Signature of the written informed consent form&#xD;
&#xD;
          -  6. Presence of a support person (for patient with cognitive disorders)&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  1. Hypersensitivity to one of the excipients (glycerin, ethanol, lecithin)&#xD;
&#xD;
          -  2. Absence of hypoalbuminemia&#xD;
&#xD;
          -  3. During the 2 months before inclusion :&#xD;
&#xD;
               -  Use of CoQ10&#xD;
&#xD;
               -  Treatment with antioxidants (vitamin C) and statins&#xD;
&#xD;
               -  Use of drugs affecting mitochondrial activity&#xD;
&#xD;
               -  Anti-cholesterol, thyroid hormones, anti-arrhythmic compounds, warfarin,&#xD;
                  metformin or clozapine&#xD;
&#xD;
          -  4. Treatment with vitamin E, calcium, magnesium and/or other vitamins with a&#xD;
             concentration superior to 149 UI during more than 3 months before inclusion&#xD;
&#xD;
          -  5. Use of drugs interfering with catacholamine metabolism (reserpine, amphetamine, or&#xD;
             inhibitors of the monoamine oxidase A, methylphenidate, cinnarizine) during the month&#xD;
             before inclusion&#xD;
&#xD;
          -  6. Non balanced treatment with anxiolytics, hypnotics, tranquillizers and/or&#xD;
             antidepressants during the month before inclusion&#xD;
&#xD;
          -  7. Hypothyroidism with thyroxin use&#xD;
&#xD;
          -  8. Epilepsy&#xD;
&#xD;
          -  9. Psychotic disorders&#xD;
&#xD;
          -  10. Pregnancy or lactation period&#xD;
&#xD;
          -  11. Woman of childbearing potential without efficient contraception&#xD;
&#xD;
          -  12. Participant to other therapeutic studies during the month before inclusion&#xD;
&#xD;
          -  13. Inability to receive a clear information on the research&#xD;
&#xD;
          -  14. Inability to participate to the totality of the study&#xD;
&#xD;
          -  15. Non affiliation to social security (beneficiary or assignee)&#xD;
&#xD;
          -  16. Refusal of signing the consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perrine Charles, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assitance Publique - Hopitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICM Institute</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia with Oculomotor Apraxia type 1</keyword>
  <keyword>CoQ10</keyword>
  <keyword>hypoalbuminemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Apraxias</mesh_term>
    <mesh_term>Cogan Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

